Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model

(2021) Sreelekshmy Mohandas et al.   iScience

Biochemical characterization of SARS-CoV-2 nucleocapsid protein

(2020) Weihong Zeng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

(2020) Jose Mateus et al.   SCIENCE

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(2020) Takuya Sekine et al.   CELL

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Humoral Immune Response to SARS-CoV-2 in Iceland

(2020) Daniel F. Gudbjartsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

(2020) Alicia T. Widge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biosensing Detection of the SARS-CoV-2 D614G Mutation

(2020) Yang Zhang et al.   TRENDS IN GENETICS

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

T Cell Responses to Whole SARS Coronavirus in Humans

(2014) C. K.-f. Li et al.   JOURNAL OF IMMUNOLOGY

The who's who of T-cell differentiation: Human memory T-cell subsets

(2013) Yolanda D. Mahnke et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1–dependent pathways

(2012) Victoria J. Philbin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer

(2012) Nikunj M. Shukla et al.   PLoS One